Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value due to falling ORR (objective response rate).
Recently, well known ROTY member Biotech Phoenix submitted this one to Idea Lab, stating that pivotal data in 4th Line GIST was compelling with efficacy as good or better than approved therapies in the 2nd/3rd line setting. He also notes